Tanya M Laidlaw Selected Research

Nasal Polyps (Nasal Polyp)

1/2022	Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease.
1/2022	Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.
1/2021	The Role of Biologics in Chronic Rhinosinusitis with Nasal Polyps.
1/2021	Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma.
1/2021	The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.
1/2020	Guidance for contemporary use of biologics in management of chronic rhinosinusitis with nasal polyps: discussion from a National Institutes of Health-sponsored workshop.
1/2020	IL-5Rα marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease.
1/2020	NSAID-ERD Syndrome: the New Hope from Prevention, Early Diagnosis, and New Therapeutic Targets.
12/2019	Longitudinal progression of aspirin-exacerbated respiratory disease: analysis of a national insurance claims database.
11/2019	Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tanya M Laidlaw Research Topics

Disease

29	Asthma (Bronchial Asthma) 01/2022 - 07/2012
21	Nasal Polyps (Nasal Polyp) 01/2022 - 04/2012
15	Inflammation (Inflammations) 01/2021 - 01/2010
12	Rhinosinusitis 01/2022 - 03/2014
8	Eosinophilia 01/2022 - 10/2013
8	Hypersensitivity (Allergy) 01/2022 - 09/2008
4	Polyps 11/2019 - 10/2015
3	Rhinorrhea 09/2018 - 03/2014
3	Pneumonia (Pneumonitis) 10/2013 - 01/2010
2	Anosmia 05/2022 - 01/2022
2	Chronic Cough 05/2022 - 12/2021
2	Cough 05/2022 - 12/2021
2	Aspirin-Induced Asthma 01/2020 - 01/2019
2	Respiratory Sounds (Crackle) 09/2018 - 03/2014
2	Bronchial Spasm 09/2018 - 11/2016
2	Respiratory Hypersensitivity 01/2017 - 07/2012
2	Pulmonary Eosinophilia (Eosinophilic Pneumonia) 10/2015 - 07/2012
2	Vascular Remodeling 07/2012 - 01/2010
1	Chronic Urticaria 01/2022
1	Arthralgia (Joint Pain) 01/2022
1	Neurogenic Inflammation 12/2021
1	COVID-19 07/2021
1	Erythema 01/2021
1	Drug-Related Side Effects and Adverse Reactions 01/2021
1	Headache (Headaches) 01/2021
1	Hyperplasia 01/2021
1	Chronic Pain 01/2021
1	Opioid-Related Disorders (Opiate Addiction) 01/2021
1	Nasopharyngitis 01/2021
1	Pain (Aches) 01/2021
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2021
1	Back Pain (Backache) 01/2021
1	Rhinitis 01/2021
1	Exanthema (Rash) 10/2020
1	Virus Diseases (Viral Diseases) 01/2020
1	Infections 01/2020
1	Cystic Fibrosis (Mucoviscidosis) 01/2020
1	Lung Injury 01/2020
1	Bronchiectasis 01/2020
1	Asthma and Nasal Polyps 12/2019
1	Atopic Dermatitis (Atopic Eczema) 11/2019
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2019
1	Hypophosphatemia 01/2017
1	Muscle Cramp (Cramp) 01/2017
1	Chest Pain (Chest Pains) 11/2016
1	Nose Diseases (Disease, Nose) 11/2016
1	Coronary Vasospasm (Coronary Artery Vasospasm) 11/2016

Drug/Important Bio-Agent (IBA)

41	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 05/2022 - 04/2012
8	Pharmaceutical PreparationsIBA 01/2022 - 05/2017
7	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2022 - 05/2017
6	dupilumabIBA 01/2022 - 09/2019
6	Cyclooxygenase 1IBA 01/2020 - 07/2016
5	CytokinesIBA 12/2021 - 07/2012
5	EnzymesIBA 01/2021 - 01/2010
4	Dinoprostone (PGE2)FDA Link 01/2022 - 07/2012
4	ProstaglandinsIBA 01/2019 - 01/2010
3	Immunoglobulin E (IgE)IBA 01/2021 - 07/2014
3	Biological ProductsIBA 01/2021 - 01/2020
3	LeukotrienesIBA 10/2020 - 10/2013
3	Leukotriene E4IBA 01/2019 - 12/2013
3	Leukotriene C4IBA 10/2015 - 12/2013
3	Prostaglandins EIBA 06/2014 - 01/2010
2	Interleukin-13IBA 01/2021 - 11/2019
2	Monoclonal AntibodiesIBA 01/2021 - 11/2019
2	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2019 - 11/2016
2	Biomarkers (Surrogate Marker)IBA 01/2019 - 07/2017
2	Proteins (Proteins, Gene)FDA Link 01/2016 - 10/2015
2	AllergensIBA 06/2015 - 01/2010
2	Thromboxane Receptors (Thromboxane Receptor)IBA 06/2015 - 07/2012
1	Antitussive Agents (Antitussives)FDA Link 05/2022
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 05/2022
1	Neurotransmitter Agents (Neurotransmitter)IBA 05/2022
1	Ion Channels (Ion Channel)IBA 12/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2021
1	mepolizumabIBA 01/2021
1	Small Cytoplasmic RNAIBA 01/2021
1	Opioid Analgesics (Opioids)IBA 01/2021
1	Interleukin-4 (Interleukin 4)IBA 01/2021
1	Interleukin-5 (Interleukin 5)IBA 01/2021
1	Immunoglobulin G (IgG)IBA 01/2020
1	InterferonsIBA 01/2020
1	InterleukinsIBA 11/2019
1	DexpramipexoleIBA 01/2019
1	Cyclooxygenase InhibitorsIBA 01/2019
1	Investigational DrugsIBA 01/2019
1	GlucocorticoidsIBA 01/2017
1	Methacholine Chloride (Methacholine)FDA Link 01/2017
1	Imatinib Mesylate (Gleevec)FDA Link 01/2017
1	Tryptases (Tryptase)IBA 01/2017
1	Thymic Stromal LymphopoietinIBA 01/2016
1	Group V Phospholipases A2IBA 01/2016
1	prostaglandin R2 D-isomerase (prostaglandin D2 synthase)IBA 01/2016
1	Phospholipases A2 (Phospholipase A2)IBA 01/2016
1	CarboxypeptidasesIBA 01/2016
1	Messenger RNA (mRNA)IBA 01/2016

Therapy/Procedure

9	Therapeutics 05/2022 - 07/2012
2	Drug Therapy (Chemotherapy) 05/2022 - 09/2008
1	Biological Therapy 01/2020
1	Drug Tapering 11/2016